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Abstract 3 
Background 4 
Inertial measurement units combined with a smartphone application (CuPiD-system) were developed 5 
to provide people with Parkinson’s disease (PD) real-time feedback on gait performance. This study 6 
investigated the CuPiD-system’s feasibility and effectiveness compared with conventional gait 7 
training when applied in the home environment. 8 
Methods 9 
Forty persons with PD undertook gait training for 30 minutes, three times per week for six weeks. 10 
Participants were randomly assigned to i) CuPiD, in which a smartphone application offered positive 11 
and corrective feedback on gait, or ii) an active control, in which personalized gait advice was 12 
provided. Gait, balance, endurance and quality of life were assessed before and after training and at 13 
four weeks follow-up using standardized tests. 14 
Results 15 
Both groups improved significantly on the primary outcomes (single and dual task gait speed) at post-16 
test and follow-up. The CuPiD group improved significantly more on balance (MiniBESTest) at post-17 
test (from 24.8 to 26.1, SD~5) and maintained quality of life (SF-36 physical health) at follow-up 18 
whereas the control group deteriorated (from 50.4 to 48.3, SD~16). No other statistically significant 19 
differences were found between the two groups. The CuPiD system was well-tolerated and 20 
participants found the tool user-friendly. 21 
Conclusion 22 
CuPiD was feasible, well-accepted and seemed to be an effective approach to promote gait training, 1 
as participants improved equally to controls. This benefit may be ascribed to the real-time feedback, 2 
stimulating corrective actions and promoting self-efficacy to achieve optimal performance. Further 3 
optimization of the system and adequately-powered studies are warranted to corroborate these 4 
findings and determine cost-effectiveness. 5 
  6 
Introduction 1 
In Parkinson’s disease (PD), gait and balance deficits, and more specifically freezing of gait 2 
(FOG), result in reduced quality of life [1]. Exercise has been shown to improve PD motor 3 
impairments in the short term [2, 3]. Also, it has been suggested that exercise effects can be 4 
enhanced by increasing subjects’ cognitive engagement with practice through the provision of cueing 5 
or biofeedback in PD [4, 5]. Cueing is defined as temporal or spatial stimuli, which regulate and 6 
facilitate repetitive movements by providing an explicit motor target. Several systematic reviews 7 
indicate that different cueing modalities have an immediate effect on gait and health related quality 8 
of life (HR-QoL) [6-8], and increase retention of learning in PD [9, 10]. In addition, cueing reduces the 9 
severity of Freezing of Gait (FOG) [9, 11, 12]. Biofeedback refers to the provision of external 10 
information during or immediately after movement, which supplements sensory (proprioceptive) 11 
pathways to guide motor performance. Although augmented feedback has been shown to be 12 
effective for improving balance [13-15] and gait [16], it usually requires cumbersome laboratory 13 
setups and specialized healthcare professionals to administer. Combined with the increasing 14 
prevalence of PD and the predicted shortage of physiotherapists [17], new ways to deliver cueing 15 
and biofeedback seem therefore warranted. 16 
Current wearable technology in PD is mainly directed towards long-term, home assessment 17 
of disease symptoms [18], rather than therapy [19]. To our knowledge, only Espay et al. investigated 18 
at-home training with wearable biofeedback technology and showed it was effective to improve gait 19 
in PD, although a control group was lacking [20]. In addition, FOG can now be detected reliably in 20 
real-time using inertial measurement units (IMUs) in a standardized setting, but home detection has 21 
not been investigated yet [21, 22]. A six week training period using a FOG specific instrumented 22 
cueing method in the laboratory, found a reduction of FOG episodes but no carry-over to daily life 23 
[23]. These results highlight the challenge of designing appropriate technology, which aims to 24 
address the needs of people with PD in the home environment [19]. 25 
The current study is part of the EU-funded CuPiD-project (www.cupid-project.eu). 1 
Innovatively, and in line with recent evolutions [24, 25], we designed a gait training application not 2 
only with a team of engineers and physiotherapists, but also with the active participation of persons 3 
with PD. The technology integrates 3 main functions: 1) measurement of gait in real-time; 2) auditory 4 
biofeedback (ABF) on one or more spatiotemporal gait parameters [26]; and 3) rhythmical auditory 5 
cueing to prevent or overcome FOG episodes [22]. The aims of the present study were to test the 6 
feasibility of training with the CuPiD system in the home environment, and to discover the 7 
differential effects of CuPiD training versus conventional home-based gait intervention on gait, 8 
balance and HR-QoL in PD. We hypothesized that both interventions would improve gait and balance 9 
outcomes, as participants would be stimulated to increase walking, but that the effects would be 10 
amplified in the CuPiD group because of the cognitive engagement by the wearable biofeedback. 11 
 12 
Methods 13 
Participants 14 
Forty PD persons were recruited by telephone from databases of the Department of 15 
Rehabilitation Sciences, KU Leuven (Belgium) and the Tel Aviv Sourasky Medical Center (Israel) 16 
(Figure 1). Participants were included if they were able to walk for 10 minutes continuously; had a 17 
score of 24 or higher on the Montreal Cognitive Assessment (MoCA); were in Hoehn & Yahr Stage II 18 
to III in ON-state and were on stable PD medication. People were excluded if they had severe medical 19 
conditions affecting gait other than PD, had hearing or visual problems precluding benefiting from 20 
auditory feedback and were likely to change medication regimen during the course of the study. 21 
Participants were allowed to continue with their usual care including their regular physiotherapy. 22 
After baseline screening, participants were randomly allocated to the CuPiD or control group per 23 
center by the researcher, who was not blind to group allocation. A stratified blocked randomization 24 
procedure was used (Hoehn & Yahr stage, having FOG or not). The study was approved by the local 25 
ethics committee of the University Hospitals Leuven and Tel Aviv Sourasky Medical Center. All 1 
participants gave written consent according to the declaration of Helsinki. 2 
CuPiD system 3 
The CuPiD system consisted of a smartphone (Galaxy S3-mini, Samsung, South Korea), a 4 
docking station and two IMUs (EXLs3, EXEL srl., Italy) with a sampling frequency of 100Hz (Figure 2A 5 
in supplementary materials). Technical features and algorithms were first validated for the detection 6 
of gait abnormalities against standard gait registration systems [26], and for FOG detection in a 7 
laboratory environment [22]. Ten people with PD (5 from each country) extensively tested the 8 
system prior to trial commencement. Battery life ensured a user-duration of up to 4 hours. 9 
Two applications were used in this study: the audio-biofeedback (ABF-gait app) and the instrumented 10 
cueing for FOG-training (FOG-cue app). Feedback and cues were provided via earphones or the 11 
smartphone’s speaker. The ABF-gait app contained: 12 
1) A large touch-screen ”Start” button, establishing the connection with the IMUs (see figure 2A); 13 
2) A menu of four training targets: cadence, stride length, symmetry and gait speed; 14 
3) A ‘therapeutic window’ allowing calibration of feedback according to the individual’s optimal 15 
gait performance [26], and set per gait parameter as a percentage above and below the 16 
median of every 5 steps (see figure 2B). Positive verbal feedback (in Dutch or Hebrew) was 17 
given when gait remained within the therapeutic window, diminishing with an exponential 18 
trend to prevent feedback overload and maximize motor learning. Corrective verbal feedback 19 
was given when gait parameters fell outside the therapeutic window. Figure 3 shows training 20 
examples of 2 PD persons (see supplementary materials). 21 
The FOG-cue app contained: 22 
1) A FOG detection sensitivity option, adjusted by the physiotherapist to low or high to 23 
accommodate excessive false positive or false negative detections. 24 
2) An exercise menu, including walking in a figure of 8, maneuvering through cluttered spaces and 1 
making turns with and without responding to a visual GO-NO-GO signal provided by the 2 
smartphone. 3 
3) Intelligent cueing options, providing continuous cueing during walking which faded when FOG 4 
occurred or was initiated when FOG was detected (based on the person’s preference). 5 
Intervention 6 
A. CuPiD training 7 
CuPiD group participants received weekly home visits from the researcher during the six week of 8 
intervention. Participants were instructed to walk at least 3 times per week for 30 minutes, according 9 
to ACSM’s exercise guidelines for health benefits [27]. They were instructed to use the ABF-gait app, 10 
which provided feedback on selected gait parameters during their walks. Participants with FOG 11 
received instruction on how to avoid FOG and practiced for an additional 30 minutes three times a 12 
week using the FOG-cue app, similar to previous work [23]. 13 
The smartphone was carried in a pocket of the participant’s clothing, except for during FOG-14 
training when the phone was handheld (to see the visual signals). Participants were taught how to 15 
apply the IMUs to their shoes (when using the ABF-gait app) and above their ankles when using the 16 
FOG-cue app. A booklet with pictures and personalized instructions was left in the home and 17 
consultation by telephone was offered in case of difficulties using the system. An optimal 18 
performance walk was performed during the initial visit and repeated twice over the 6-week study 19 
period to calibrate the ABF-gait app. Spatiotemporal parameters and FOG-cue settings were on 20 
average 4 times adjusted by the researcher during weekly visits. 21 
Participants were asked to record the frequency and duration of their training sessions in a 22 
diary. The CuPiD system also recorded the duration of walks with the system. Training data were 23 
provided in summary statistics, consisting of simple displays of positive and corrective feedback 24 
received and number of steps performed. 25 
Control training 1 
The control group also received weekly visits by the same researcher for six weeks and was 2 
provided with the same practice schedule, personalized approach and recommendations for training, 3 
except for the CUPID system. Control participants also recorded the frequency and duration of their 4 
training sessions in a diary. People allocated to this group were informed about the documented 5 
effectiveness of the intervention. 6 
Assessment procedure and outcomes 7 
During the first session (pre-test), in- and exclusion criteria were checked and baseline values 8 
of the primary and secondary outcomes collected. The same outcomes were assessed after the 6 9 
weeks intervention (post-test) and after a 4 week (follow-up) period by the same assessor at each 10 
clinical center. Testers were not blinded to group allocation. Measurements’ order was standardized 11 
within the test procedure and conducted when participants were optimally medicated, about 1 hour 12 
after PD medication intake. 13 
Primary outcomes were gait speed under usual and dual task conditions. We were 14 
particularly interested in detecting changes in DT gait speed, as it may better represent improved 15 
gait automaticity than single task outcomes. Participants were asked to walk for one minute over an 16 
instrumented walkway (PKMAS, Protokinetics, USA): (1) at comfortable speed and (2) while reciting 17 
as many words as possible starting with a pre-specified letter. Secondary gait, balance and HR-QoL 18 
outcomes included the 2 Minute Walk Test (2MWT) [28], the mini-Balance Evaluation Systems Test 19 
(MiniBESTest) [29], the Four Square Step Test (FSST) [30], the Falls Efficacy Scale-International (FES-I) 20 
[31] and the Physical Activity Scale for the Elderly (PASE) [32]. FOG severity was determined by the 21 
New-FOG questionnaire (NFOG-Q) [33] and the Ziegler protocol [34]. Disease severity was quantified 22 
using the Movement Disorders Unified Parkinson’s Disease Rating Scale – motor examination (UPDRS 23 
III) [35]. Cognitive assessments included Color Trail Test (CTT) A and B [36] and verbal fluency (VF) 24 
scores in sitting and walking. Quality of life was determined by the Short Form 36 Health Survey (SF-25 
36) [37]. At post-test, a 5-item Likert scale investigated whether participants found the CuPiD system 1 
user-friendly or not (1 = no agreement and 5 = total agreement). 2 
Statistical analysis 3 
Kolmogorov-Smirnov analysis and Levene’s test evaluated the data distribution. In case of 4 
abnormal distributions, non-parametric analyses were performed. As this did not lead to different 5 
results, only parametric test results are reported. 6 
To compare baseline characteristics and adherence outcomes between both groups, an 7 
independent samples T-test was used for continuous and a chi-square for categorical variables. A 2 8 
(group) by 3 (time: pre-test/post-test/follow-up) repeated measures ANOVA evaluated differences 9 
for the dependent variables on the primary and secondary outcomes, being the independent 10 
variables. Because of the exploratory nature of this trial, Fisher’s LSD post-hoc analyses were applied. 11 
Effect sizes expressed as partial eta squared (ɳ²) are reported for the most important findings. The 12 
level of statistical significance was set at α = 0.05. 13 
We report the data from all participants who completed the 6 weeks of training (per protocol 14 
analysis) and also conducted an intention-to-treat analysis with a last observation carried forward 15 
method to impute missing values. Statistical analysis was performed using SPSS version 22 (IBM, 16 
USA). 17 
 18 
Results 19 
Twenty-two participants were allocated to CuPiD, of which 20 completed training. Eighteen 20 
participants were allocated to the control arm, all of whom completed training (Figure 1). Reasons 21 
for dropout (N=2) were unrelated to CuPiD in one person. However, the second person was unable 22 
to cope with the CuPiD system without supervision at home. Both training groups were similar at 23 
baseline (see supplementary materials: table S1). Fourteen CuPiD participants and 10 control 24 
participants experienced FOG. Only 11 participants (29%) had used a smartphone before entering the 1 
study. 2 
 3 
Gait 4 
There were no interaction effects for the primary outcomes (table 1), gait speed under single 5 
tasking (F(2,108)=1.11, p=0.34, ɳ² = 0.03) and gait speed under dual tasking (F(2,108)=1.14, p=0.33, ɳ² = 6 
0.03). Also the group differences for the primary outcomes, were not significantly different (Single 7 
tasking: F(1,108)=0.15, p=0.70, ɳ² = 0.01; Dual tasking: F(1,108)=0.19, p=0.66, ɳ² = 0.01). However, there 8 
was a main effect of time (Single tasking: F(2,108)=14.31, p<0.001, ɳ² = 0.29; Dual tasking: F(2,108)=9.57, 9 
p<0.001, ɳ² = 0.23). These results indicate that both groups improved gait speed during single and 10 
dual tasking from pre-test to post-test, whereby the CuPiD group improved their gait speed with 11 
9.0% and 13.5% and the control group with 5.2% and 5.8% for single and dual tasking, respectively. 12 
Other gait outcomes showed a similar pattern of results and most gait benefits were maintained at 13 
follow-up in both groups. 14 
 15 
Balance 16 
A significant time by group interaction was found for the miniBESTest (F(2,108)=3.73, p=0.04, ɳ² 17 
= 0.11), indicating that the improvement in balance for the CuPiD group was significantly greater 18 
than the control group at post-test (table 1). However, this effect was not maintained at follow-up. 19 
This result was also reflected with a trend towards a significant interaction effect of time by group for 20 
the FSST (F(2,108)=3.38, p=0.09, ɳ² = 0.10). 21 
 22 
Endurance 23 
 The aforementioned gait improvements were also reflected in the 2MWT which showed a 24 
significant main effect of time (F(2,108)=4.32, p<0.005, ɳ² = 0.11) as shown in table 1. 25 
 26 
Health related quality of life 1 
A significant time by group interaction was found for the physical health score of the SF-36 2 
(F(2,108)=1.85, p<0.05, ɳ² = 0.06), indicating that the control group experienced a decrease in self-3 
reported physical health at follow-up, while the CuPiD group did not. 4 
 5 
There were no significant between-group or within-group differences for FOG outcomes and 6 
cognitive measures. Intention-to-treat analysis yielded similar results with the exception that the 7 
time by group interactions for the MiniBESTest and SF-36 (physical health) were no longer significant 8 
(both p=0.07). 9 
 10 
Feasibility 11 
Adherence data (Table 2) showed that the CuPiD group spent less time training compared to 12 
the control group, while the number of training sessions was identical (CuPiD: 28 ± 9 sessions; 13 
control: 28 ± 10 sessions; p=0.91). Training duration was based on the CuPiD system logs for the 14 
CuPiD group, and diary data for the control group. When checking for differences between diaries 15 
and CuPiD logs in 13 CuPiD participants, diary notations (701 ± 304 min.) were not significantly 16 
different from CuPiD logs (646 ± 254 min.; p=0.25). Participants with incomplete diary data, were 17 
excluded from this analysis. 18 
In general, participants were very positive about the CuPiD system, as scores on user-19 
friendliness were on average above 4 on a 5-point scale. However, attaching and removing the IMUs 20 
and using the CuPiD system without technical support resulted in more variable answers (Table 1). It 21 
was observed that participants with previous smartphone experience had the least problems using 22 
the CuPiD system. Some participants were so enthusiastic about the system that they expressed 23 
disappointment after its withdrawal. 24 
 25 
Discussion 26 
This phase II RCT investigated the feasibility of the CuPiD system and its effectiveness on gait 1 
and balance, compared to conventional gait training in people with PD. The system was well-2 
accepted and showed to be useful for providing minimally supervised at-home gait training. Both 3 
study arms improved on the primary outcomes of gait speed under comfortable and dual task 4 
conditions at post-test and at follow-up. The CuPiD approach demonstrated to be better at 5 
improving balance than conventional gait training in people with PD. 6 
Despite the non-superior findings of the CuPiD system for gait, the results revealed a larger 7 
improvement in gait speed during both comfortable (9.0%) and dual task conditions (13.5%), 8 
whereas controls improved gait speed by only 5.2% and 5.8%. According to the recommendations by 9 
Hass et al., the control group’s effect sizes can be interpreted as small [38], whereas those of the 10 
CuPiD group can be considered as clinically moderate and as comparable to other cueing and 11 
treadmill studies [9, 16, 39]. These results are the more notable, considering that total training time 12 
was lower in the CuPiD group, suggesting that the CuPiD system may have improved training 13 
efficiency. 14 
In contrast to gait, we found an interaction effect for the MiniBESTest balance outcome 15 
favoring the CuPiD group. However, it should be noted that the between-group mean difference for 16 
the MiniBESTest of 1.7 points is below the smallest real difference of 3.4 points [40]. CuPiD 17 
participants also tended to improve more than controls on the FSST, another test of dynamic 18 
stability, requiring fast steps in different directions over a small obstacle. Together, these findings 19 
suggest that CuPiD induced benefits of dynamic stability, which may be ascribed to the fact that 20 
CuPiD targeted larger step sizes and greater gait stability. 21 
There were no between- or within-group effects on FOG, although pre- to post-test 22 
differences of 1.5 points in NFOG-Q scores were found in favor of the CuPiD group. Since both groups 23 
devoted less time to training FOG, it is possible that the dose was insufficient to be effective. In 24 
addition, FOG training was only undertaken by 17 participants. Therefore, the study was not 25 
powered to detect significant differences. 26 
This study showed that the CuPiD group trained as much as the control group in terms of 1 
training sessions, but had a lower training duration. Possible explanations could be related to the 2 
self-reporting of adherence, overestimating actual compliance for reasons of social desirability. 3 
However, when training diaries and CuPiD logs were compared, no significant differences were 4 
detected, albeit in participants with complete diaries only. The fact that CuPiD participants were 5 
aware that their training was logged, may also have contributed to this finding. The number of 6 
training sessions was similar in both groups, indicating that the intention to train was equal in both 7 
groups. Also, the reported training duration is in line with earlier reported adherence of 8 
approximately 80% in home-based PD interventions [41, 42]. The CuPiD system was used with 9 
minimal supervision, while most participants were unfamiliar with a smartphone. Except for 10 
difficulties with the correct placement of the IMUs and the touchscreen the system was very well-11 
tolerated as indicated by the positive scores on the user-friendliness scale. 12 
Lack of statistical confirmation of the CuPiD system’s benefits may indicate that it does not 13 
offer an added clinical value. Alternatively, the study may have been underpowered to show a 14 
surplus effect. Post-hoc power calculations based on the dual task gait speed results showed that 164 15 
(82 per group) persons would be required to achieve the desired power of 0.80 assuming effect sizes 16 
of 13.5% for the CuPiD group and 5.8% for controls. However, when compared against a passive 17 
control group, a total of 54 (27 per group) participants would suffice. Other limitations which may 18 
have influenced the trial outcomes, were the lack of assessor blinding for group allocation and 19 
uncorrected post-hoc analyses for multiple comparisons. Also, the placebo effect resulting from 20 
increased attention during therapy was not controlled for and we did not take usual care 21 
characteristics into consideration. Despite these drawbacks, we conclude that the CuPiD system was 22 
feasible for unsupervised home-use and was an effective approach for gait and balance training in 23 
PD. Given the shorter training duration with the CuPiD systems, these benefits may possibly be 24 
associated with the online biofeedback model, enhancing training efficiency. Large scale clinical trials 25 
to investigate its long-term use and cost-effectiveness are indicated before future implementation 1 
can be considered. 2 
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Table 1 Outcomes of PD persons who completed the training period 
 CuPiD (n=20)  Control (n=18)  Effects 
Variables Pretest Posttest Follow-up  Pretest Posttest Follow-up  Time Group Time x Group 
Comfortable gait 
Gait speed [m/s] 1.11 (0.23) 1.21 (0.24)
a 
1.22 (0.23)
a 
 1.16 (0.14) 1.22 (0.14)
a 
1.24 (0.17)
a 
 P<0.001 P=0.70 P=0.34 
Stride length [m] 1.18 (0.22) 1.26 (0.21)
a 
1.26 (0.21)
a 
 1.26 (0.16) 1.32 (0.14)
a 
1.31 (0.17)
a 
 P<0.001 P=0.31 P=0.31 
DS time [% GCT] 32.42 (4.62) 30.71 (3.99)
a 
30.59 (4.28)
a 
 29.51 (3.12) 28.79 (3.26)
a 
28.88 (3.59)
a 
 P<0.01 P=0.07 P=0.17 
Dual task gait            
Gait speed [m/s] 0.96 (0.24) 1.09 (0.28)
a 
1.07 (0.27)
a 
 1.03 (0.12) 1.09 (0.11)
a 
1.09 (0.17)
a 
 P<0.001 P=0.66 P=0.33 
Stride length [m] 1.07 (0.22) 1.16 (0.26)
a 
1.14 (0.24)
a
  1.15 (0.14) 1.21 (0.11)
a 
1.19 (0.18)
a 
 P<0.001 P=0.35 P=0.51 
DS time [% GCT] 34.70 (4.81) 32.64 (4.60)
a 
32.94 (4.75)  31.78 (3.26) 31.02 (3.58)
a 
31.51 (4.05)  P<0.01 P=0.12 P=0.22 
Balance            
MiniBESTest [0-32] 24.75 (5.61) 26.10 (4.64)
a
 24.95 (4.78)  25.33 (4.04) 24.44 (4.96) 25.00 (4.89)  P=0.79 P=0.82 P=0.04 
FSST [s] 11.02 (3.57) 9.70 (2.28) 9.86 (3.34)
a 
 10.26 (2.21) 10.51 (3.53) 10.12 (2.59)
a 
 P<0.05 P=0.92 P=0.09 
FES-I [16-64] 26.90 (7.21) 27.35 (9.45) 26.74 (9.57)  27.28 (10.02) 27.82 (12.07) 28.00 (9.93)  P=0.91 P=0.84 P=0.89 
Endurance and physical capacity 
2 MWT [m] 145.56 (38.17) 157.54 (39.23)
a 
152.47 (43.38)  150.09 (25.89) 153.89 (25.20)
a 
154.97 (24.18)  P<0.005 P=0.95 P=0.15 
PASE [0-400] 125.86 (85.56) 115.31 (73.77) 102.30 (68.55)  103.30 (60.37) 102.66 (50.00) 99.92 (48.19)  P=0.18 P=0.52 P=0.56 
Disease severity 
UPDRS III [0-132] 28.35 (14.77) 28.15 (15.57) 30.85 (14.26)  33.77 (14.36) 31.00 (14.62) 34.65 (15.21)  P=0.09 P=0.44 P=0.64 
Freezing of Gait 
1
 
NFOG-Q [0-28] 14.43 (7.84) 12.93 (7.65) 13.93 (8.27)  13.70 (7.82) 15.10 (6.57) 15.70 (7.30)  P=0.49 P=0.73 P=0.19 
Ziegler [0-36] 5.50 (8.25) 5.07 (6.97) 5.00 (6.67)  4.40 (4.12) 4.00 (6.91) 4.30 (4.27)  P=0.79 P=0.69 P=0.93 
Cognition 
CTT-A [s] 73.65 (34.67) 58.70 (26.27) 64.30 (29.87)  59.78 (19.16) 69.94 (47.08) 64.77 (26.59)  P=0.08 P=0.67 P=0.08 
CTT-B [s] 136.32 (59.42) 142.95 (67.38) 126.00 (60.25)  122.33 (66.07) 119.78 (56.24) 120.65 (58.93)  P=0.23 P=0.36 P=0.25 
VF Sit [#] 30.05 (12.19) 29.50 (14.89) 27.75 (14.43)  31.78 (16.95) 31.22 (17.84) 32.88 (22.02)  P=0.86 P=0.58 P=0.46 
VF Walk [#] 11.00 (5.06) 10.20 (4.56) 10.35 (5.58)  10.28 (6.32) 10.33 (6.82) 11.18 (7.49)  P=0.59 P=0.99 P=0.47 
Quality of life 
SF-36 [0-100] 58.59 (18.60) 59.76 (17.95) 59.46 (17.13)  53.24 (16.55) 59.28 (18.73) 53.81 (20.42)  P=0.23 P=0.51 P=0.65 
SF-36 Phys. health [0-100] 53.79 (18.50) 53.28 (18.45) 54.80 (16.48)  50.41 (15.60) 56.67 (17.32) 48.29 (15.54)
b 
 P=0.21 P=0.71 P<0.05 
SF-36 Ment. health [0-100] 59.76 (18.01) 63.56 (18.41) 60.60 (18.05)  55.00 (18.69) 58.13 (20.04) 56.59 (24.21)  P=0.38 P=0.44 P=0.75 
 
CuPiD System usability [1-5] 
I can turn on the smartphone easily 4.5 (0.9)         
I can turn on the CuPiD applications easily 4.6 (0.7)         
I think CuPiD is simple to use 4.3 (0.8)         
I can attach/remove the sensors easily 4.0 (1.3)         
I think I can use the system independently 4.0 (1.2)         
m: meters; s: seconds; DS: Double Support; GCT: gait cycle time; Phys: Physical; Ment: Mental 
1 
analysis performed only on PD persons reporting freezing of gait; 
a
 significantly different from pretest; 
b
 significantly different from posttest 
Values are presented as mean (± standard deviation) 
 
 
Table 2 Adherence data 
 CuPiD * Control ** p- value 
Overall    
PD persons [#] 20 18  
Total duration [minutes] 649.5 (234.7) 923.8 (342.6) <0.01 
Sessions [#] 28.3 (8.7) 27.9 (10.3) 0.91 
ABF-app/Gait advice    
PD persons [#] 20 18  
Total duration [minutes] 494.7 (274.5) 742.7 (286.7) 0.01 
Sessions [#] 20.7 (6.5) 20.7 (6.1) 0.99 
FOG-cue/FOG advice    
PD persons [#] 10 7  
Total duration [minutes]
 
309.6 (141.5) 465.6 (179.1) 0.06 
Sessions [#] 16.3 (4.5) 18.6 (1.5) 0.17 
* Based on CuPiD-system adherence data 
** Based on diary adherence data 
Values are presented as mean (± standard deviation) 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Participated in Post- and Follow-up assessments for intention-to-treat analysis 
 
Figure 1 Study flowchart 
  
Assessed for eligibility (n=53) 
Ineligible (n=13) 
 Not meeting inclusion criteria (n=9) 
 Declined to participate (n=4) 
Lost to follow-up (n=0) 
Dropout (n=2) 
 Unrelated medical reason (n=1) 
 Related with unsupervised CuPiD training (n=1)* 
Allocated to CuPiD group (n=22) 
 Gait advice + ABF-app (n=22) 
Freezing advice + FOG-app (n=12) 
 Did not receive allocated intervention (n=0) 
Dropout (n=0) 
Allocated to control group (n=18) 
 Gait advice (n=18) 
Freezing advice (n=7) 
 Did not receive allocated intervention (n=0) 
Lost to follow-up (n=1) 
 Participant unavailable for assessment (n=1) 
Stratified Allocation 
Follow-up (4 weeks) 
Post-test (6 weeks) 
Randomized (n=40) 
Completed training (n=20) 
Intention-to-treat (n=22) 
 
Completed training (n=18) 
Intention-to-treat (n=18) 
Analysis 
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Figure 2A illustrates the CuPiD system with the foot-mounted IMUs and the single large touchscreen 
button on the smartphone; 2B shows a schematic overview of the ABF-gait app with at the top a 
recording of a clinical optimal reference walk, which was captured under the therapist’s supervision. 
The median value is then used as the reference value (full horizontal line). The pre-set therapeutic 
window (dotted horizontal lines) are the percentages above and below the reference value as 
determined by the therapist. 
  
Table S1 Descriptive characteristics of training groups 
 CuPiD (n=20) Control (n=18) p- value 
Demographics    
Age [yrs] 67.30 (8.13) 66.11 (8.07) 0.65 
Gender [m/f] 17/3 13/5 / 
Persons with FOG [#] 14 10 0.50 
Smartphone users [#] 6 5 1.00 
Disease severity    
Disease duration [yrs] 10.65 (5.39) 11.67 (7.63) 0.64 
MDS UPDRS III [0-132] 28.35 (14.77) 33.77 (14.36) 0.27 
H&Y (2/2.5/3) 12/3/5 13/2/3 / 
Cognition    
MoCA [0-0-30] 26.95 (2.19) 26.72 (2.11) 0.75 
Yrs: years; m: male; f: female 
Values are presented as mean (± standard deviation) 
 
  
  
Examples of training performance and feedback in two participants using the CuPiD ABF function. 
Panels A and C show (i) number of positive and corrective feedback events (y-axis) for a 
participant across sessions during the 6 training weeks (x-axis) and (ii) number of steps taken (y-axis) 
during the training sessions (x-axis). 
Panels B and D, show details of feedback provided during the fourth-last session with on the 
x-axis the gait cycles per 30 minutes and on the y-axis % difference from the reference value of the 
training parameter that was targeted. Red dotted lines indicate the therapeutic window. The red 
dots indicate when corrective feedback was provided. The green dots indicate moments of positive 
feedback. 
Example 1. Panel B shows that this participant trained stride length as the primary parameter 
and gait speed as the secondary parameter. Initial gait speed was too fast, which the participant 
corrected by adjusting stride length. This resulted in corrective feedback to ‘take larger steps’. By the 
end of the session, the participant was able to keep both stride length and gait speed within the 
therapeutic window. If both the primary and secondary training parameters were outside the 
therapeutic window, only feedback was provided for the primary outcome, so as not to confuse the 
participant (example indicated by the black arrow in panel B). 
Example 2. Panel D shows stride length to be the sole training parameter for this participant. 
By the end of the 30 minutes, it became difficult to maintain stride length, resulting in corrective 
feedback to ‘take larger steps’. From the black arrow onwards, the system automatically increased 
the therapeutic window as not to overburden the participant with corrective feedback. 
